Results 51 to 60 of about 36,112 (211)

Evidence for adaptive explanations of semelparity in animals

Biological Reviews, EarlyView.
ABSTRACT Semelparity, the reproductive strategy of reproducing once, is widespread but uncommon in animals. Classes of models to explain the evolution of semelparity are based either on age structure and mortality schedules – demographic models in which high post‐reproductive mortality risk favours high reproductive effort and semelparity results from ...
Diana O. Fisher, Roberto Salguero‐Gómez   +1 more
wiley   +1 more source

FAM107A loss facilitates TTK‐OPTN‐mediated mitophagy to drive docetaxel resistance in castration‐resistant prostate cancer

Interdisciplinary Medicine, EarlyView.
In the progression of docetaxel resistance, downregulation of FAM107A releases its transcriptional repression of TTK, leading to TTK upregulation. TTK enhances the interaction and phosphorylation of OPTN. This activates mitophagy in tumor cells, facilitates clearance of damaged mitochondria, reduces intracellular reactive oxygen species accumulation ...
Yishan Zhang, Fan Zou, Mingdong Wang, Chenyue Wu, Yingwei Xie, Yongjun Quan, Wei Yan, Yupeng Zheng, Lianhua Li, Yuexin Liu, Jian Yu, Hao Ping   +11 more
wiley   +1 more source

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer

IJU Case Reports, 2019
Introduction Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration‐resistant prostate cancer. Case presentation A 62‐year‐old patient with a bone metastatic castration‐resistant prostate cancer was started ...
Yoshinori Yanai, Takeo Kosaka, Hiroshi Hongo, Mototsugu Oya   +3 more
doaj   +1 more source

Systemic treatment for metastatic prostate cancer

Asian Journal of Urology, 2019
The management of metastatic prostate cancer (mPCa) has changed over the past ten years. Several new drugs have been approved with significant overall survival benefits in metastatic castration resistant prostate cancer (PCa) including chemotherapy ...
Gwenaelle Gravis
doaj   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source

DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER

Медицинский совет, 2016
Prostate cancer (PCa) is a hormonsensitive tumor. Due to the discovery of the androgen receptor (AR) it became possible to implement the antiandrogens as drugs blocking testosterone Binding to the AR into routine clinical practice.
S. V. MISHUGIN, A. A. GRITSKEVICH, I. G. RUSAKOV   +2 more
doaj   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, EarlyView.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Castration-resistant prostate cancer: systemic therapy in 2012

Clinics, 2012
Prostate cancer is the most common non-cutaneous neoplasm in the male population worldwide. It is typically diagnosed in its early stages, and the disease exhibits a relatively indolent course in most patients. Despite the curability of localized disease
Fernando C. Maluf, Oren Smaletz, Daniel Herchenhorn   +2 more
doaj   +1 more source

Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone‐Sensitive Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Upfront treatment intensification with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor has become a standard approach for metastatic hormone‐sensitive prostate cancer (mHSPC). However, prognosis remains poor for some patients despite second‐generation androgen receptor antagonist‐based doublet therapy.
Saizo Fujimoto, Tsuyoshi Morita, Yutaka Yamamoto, Teruo Inamoto, Keita Tamura, Yuki Yoshikawa, Ryoichi Maenosono, Akihito Takeuchi, Kiyoshi Takahara, Seitetsu Sugiyama, Kazumasa Komura, Takafumi Yanagisawa, Wataru Fukuokaya, Takahiro Kimura, Kazutoshi Fujita   +14 more
wiley   +1 more source

Survival after spinal surgery for metastases in men with castration-sensitive vs castration-resistant prostate cancer: a nationwide register-based study

Scientific Reports
This nationwide register-based cohort study examined the association between castration status and postoperative survival in men who had undergone surgery for spinal metastases from prostate cancer. Bone metastases are common in prostate cancer, with the
Johan Wänman, Mehdy Farhang, Helena Nyström, Johan Styrke, Christel Häggström, Pär Stattin, Sead Crnalic   +6 more
doaj   +1 more source